Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:CTMXNASDAQ:IPSCNASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.99-3.9%$1.83$1.43▼$4.26$199.82M1.62145,007 shs150,325 shsCTMXCytomX Therapeutics$2.37-5.2%$2.06$0.40▼$3.10$191.07M2.052.20 million shs1.99 million shsIPSCCentury Therapeutics$0.55-0.9%$0.56$0.34▼$3.29$47.83M1.78553,785 shs361,605 shsMNPRMonopar Therapeutics$37.20+2.6%$35.99$1.72▼$54.30$227.66M1.01360,924 shs49,658 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+2.49%+0.98%+29.56%-42.62%CTMXCytomX Therapeutics0.00%+10.67%-5.68%+477.06%+93.02%IPSCCentury Therapeutics0.00%+7.96%-9.14%+35.89%-75.00%MNPRMonopar Therapeutics0.00%+6.76%-3.34%+24.16%+896.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune1.9606 of 5 stars3.53.00.00.00.60.80.6CTMXCytomX Therapeutics3.7931 of 5 stars3.51.00.04.70.01.71.3IPSCCentury Therapeutics2.0324 of 5 stars3.53.00.00.00.01.70.6MNPRMonopar Therapeutics2.8083 of 5 stars3.45.00.00.01.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00503.02% UpsideCTMXCytomX Therapeutics 3.00Buy$5.33125.04% UpsideIPSCCentury Therapeutics 3.00Buy$4.20663.50% UpsideMNPRMonopar Therapeutics 2.83Moderate Buy$60.0061.29% UpsideCurrent Analyst Ratings BreakdownLatest IPSC, CTMX, MNPR, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.005/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.005/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.44N/AN/A$1.29 per share1.54CTMXCytomX Therapeutics$138.10M1.38$0.34 per share6.91($0.01) per share-237.00IPSCCentury Therapeutics$114.90M0.41N/AN/A$1.90 per share0.29MNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.484.94N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)Latest IPSC, CTMX, MNPR, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.531.53CTMXCytomX TherapeuticsN/A1.731.73IPSCCentury TherapeuticsN/A11.7011.70MNPRMonopar TherapeuticsN/A36.9136.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%CTMXCytomX Therapeutics67.77%IPSCCentury Therapeutics50.20%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%CTMXCytomX Therapeutics6.60%IPSCCentury Therapeutics5.00%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableCTMXCytomX Therapeutics17080.62 million75.30 millionOptionableIPSCCentury Therapeutics17086.16 million81.85 millionOptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionableIPSC, CTMX, MNPR, and ACIU HeadlinesRecent News About These CompaniesMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Cantor FitzgeraldJuly 7 at 8:51 AM | marketbeat.comChardan Capital Comments on MNPR FY2025 EarningsJune 29, 2025 | americanbankingnews.comFY2025 Earnings Forecast for MNPR Issued By Chardan CapitalJune 29, 2025 | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 28, 2025 | americanbankingnews.comWhat is Chardan Capital's Forecast for MNPR FY2025 Earnings?June 27, 2025 | marketbeat.comChardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives BuyJune 26, 2025 | finance.yahoo.comInstitutional investors own a significant stake of 29% in Monopar Therapeutics Inc. (NASDAQ:MNPR)June 23, 2025 | finance.yahoo.comChardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy RecommendationJune 23, 2025 | msn.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 23, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan CapitalJune 23, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher - Time to Buy?June 12, 2025 | marketbeat.comMonopar Therapeutics Inc.: Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced CancersJune 11, 2025 | finanznachrichten.deWall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should KnowJune 11, 2025 | zacks.comMonopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced CancersJune 11, 2025 | globenewswire.comMonopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%June 3, 2025 | msn.comMonopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 3, 2025 | globenewswire.comMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 14, 2025 | manilatimes.netMMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 13, 2025 | globenewswire.comMonopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025May 8, 2025 | nasdaq.comMonopar Presents ALXN1840 Late-Breaker Data at EASL 2025May 7, 2025 | globenewswire.comWhy Monopar Therapeutics Inc. (MNPR) is Surging in 2025April 30, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, CTMX, MNPR, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$1.99 -0.08 (-3.86%) As of 04:00 PM EasternAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.CytomX Therapeutics NASDAQ:CTMX$2.37 -0.13 (-5.20%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.05 (+2.32%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Century Therapeutics NASDAQ:IPSC$0.55 -0.01 (-0.90%) Closing price 04:00 PM EasternExtended Trading$0.58 +0.03 (+6.34%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Monopar Therapeutics NASDAQ:MNPR$37.20 +0.95 (+2.62%) Closing price 04:00 PM EasternExtended Trading$36.07 -1.13 (-3.05%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.